HEALTHCARE PROFESSIONAL RESOURCES
- Metastatic
Breast CancerCLOSE THE TABThe ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Advanced Non–SmallCell Lung CancerCLOSE THE TAB
Advanced Squamous NSCLC and the Assessment of Tumor Response Video
Explore the characteristics of advanced squamous NSCLC and its clinical manifestations.
The ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Understanding Squamous NSCLC Through Virtual Reality
The NanoExplorer is an immersive, 360-degree virtual reality experience that highlights the type of patients with aNSCLC who are appropriate for treatment with ABRAXANE + carboplatin by taking the doctor on a journey inside a patient’s body to explore tumor histology, PD-L1 expression level, and actionable mutation status. Set up a presentation in your office today.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- MetastaticPancreatic CancerCLOSE THE TAB
The ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
MPACT Study Videos
Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (MPAC) using ABRAXANE + gemcitabine in the first-line setting.
MPACT Study Design
Dr. Kim presents the study design and results in the MPACT study.MPACT Efficacy
Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).MPACT Safety
Dr. Kim presents the safety results for ABRAXANE in the MPACT study.MPACT Dosing
Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Knowledge Is Power in Treating MPAC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.
NEJM Clinical Reprint
Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.
MPAC Dosing Card
Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
MPAC NCCN Flashcard
Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Knowledge Is Power in Treating MPAC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.
NEJM Clinical Reprint
Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.
MPAC Dosing Card
Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
MPAC NCCN Flashcard
Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
- Metastatic Breast CancerCLOSE THE TAB
The ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Advanced Non–Small Cell Lung CancerCLOSE THE TAB
Advanced Squamous NSCLC and the Assessment of Tumor Response Video
Explore the characteristics of advanced squamous NSCLC and its clinical manifestations.
The ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Understanding Squamous NSCLC Through Virtual Reality
The NanoExplorer is an immersive, 360-degree virtual reality experience that highlights the type of patients with aNSCLC who are appropriate for treatment with ABRAXANE + carboplatin by taking the doctor on a journey inside a patient’s body to explore tumor histology, PD-L1 expression level, and actionable mutation status. Set up a presentation in your office today.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic Pancreatic CancerCLOSE THE TAB
The ABRAXANE Journey: A History of Looking Ahead
Learn about the role ABRAXANE plays in treatment of MBC, NSCLC, and MPAC through the stories of patients, caregivers, advocacy groups and the principal investigators of the ABRAXANE pivotal trials.
MPACT Study Videos
Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (MPAC) using ABRAXANE + gemcitabine in the first-line setting.
MPACT Study Design
Dr. Kim presents the study design and results in the MPACT study.MPACT Efficacy
Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).MPACT Safety
Dr. Kim presents the safety results for ABRAXANE in the MPACT study.MPACT Dosing
Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Knowledge Is Power in Treating MPAC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.
NEJM Clinical Reprint
Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.
MPAC Dosing Card
Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
MPAC NCCN Flashcard
Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Knowledge Is Power in Treating MPAC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring MPAC patients receive the most appropriate treatments.
NEJM Clinical Reprint
Results from the Phase III Study: ABRAXANE plus gemcitabine for MPAC.
MPAC Dosing Card
Dosing Instructions for ABRAXANE MPAC indication including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
MPAC NCCN Flashcard
Learn about ABRAXANE + gemcitabine’s NCCN Category 1 recommendation in metastatic pancreatic cancer patients with good performance status (ECOG 0-1) and as a reasonable option for patients with KPS 70.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.